EUVIMEDEUVIMED entdecken
Crossref

A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors

Shuang Lu, Shuo Wang, Xueying Tang, Yangxu Gui, Jiawei Lian, Xinrong Liu, Yanzhi Song, Yihui Deng iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Shuang Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No. 103, Shenyang 110016, China. Hauptthemen laut MEDLINE: Liposomes, Quinolines, N-Acetylneuraminic Acid, Atherosclerosis. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular disease (ASCVD) poses a severe threat to human health, and the global prevalence of atherosclerosis-related diseases continues to rise, necessitating urgent exploration of novel strategies. Inspired by the close links between tumors and atherosclerosis (AS), as well as the clinical reality of their comorbidity, the present study encapsulated pitavastatin within liposomes and modified them with sialic acid-cholesterol (SA-CH) to achieve targeted drug delivery via peripheral blood neutrophils (PBNs). Compared to oral pitavastatin administration, sialic acid-modified pitavastatin liposomes (PIT-SAL) demonstrated superior efficacy in attenuating disease progression in atherosclerotic mice, with sustained therapeutic effects even after treatment cessation, suggesting the potential for eradication of AS. Notably, PIT-SAL additionally exhibited antitumor potential by effectively reducing tumoral cholesterol accumulation while enhancing T-cell infiltration. Collectively, our preliminary findings highlight the great translational potential of PIT-SAL as a targeted therapy for both AS and tumors, offering a potential breakthrough in managing these interconnected diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesQuinolinesN-Acetylneuraminic AcidAtherosclerosisNeoplasmsAnimalsMiceCholesterolNeutrophilsHumansMice, Inbred C57BLMaleFemaleDrug Delivery Systems

Stichwörter der Autor:innen

AtherosclerosisImmune plaqueLiposomeNeutrophilsPitavastatinTumor

Substanzen

LiposomespitavastatinQuinolinesN-Acetylneuraminic AcidCholesterol

Autor:innen und Institutionen

  • College of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, No. 103, Shenyang 110016, China.

ORCID-Profile: Yihui Deng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lu, S., Wang, S., Tang, X., Gui, Y., Lian, J., Liu, X., Song, Y., & Deng, Y. (2026). A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01434

Vancouver

Lu S, Wang S, Tang X, Gui Y, Lian J, Liu X, et al. A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01434

BibTeX
@article{Lu2026,
  author = {Lu, Shuang and Wang, Shuo and Tang, Xueying and Gui, Yangxu and Lian, Jiawei and Liu, Xinrong and Song, Yanzhi and Deng, Yihui},
  title = {A Two Birds with One Stone Strategy: Sialic Acid-Modified Pitavastatin Liposomes for Combating Atherosclerosis and Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01434}
}
Kostenlos starten →